Morgan Stanley: NVIDIA To Earn $10 Billion In Revenue From Blackwell Chips Alone In Q4 2024

wccftech.com:

This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.

Wall Street is rapidly pivoting away from gnashing its proverbial teeth over NVIDIA's peaking margins just a few weeks back to now rushing to incorporate the Blackwell production ramp-up in its collective bullish thesis, replete with expectations of a phenomenal surge in revenue from the GPU manufacturer's latest flagship product.

For the benefit of those who might not be aware, the rumors of a Blackwell architecture design flaw had dominated the narrative around NVIDIA throughout the summer, with analysts contending that the flaw's rectification would relegate the Blackwell production ramp-up to a predominantly calendar year 2025 phenomenon.

Related Story NVIDIA’s GeForce RTX 40 Series GPUs See Widespread Price Drops From UK Retailers

Then, while announcing its earnings for the June-ending quarter, NVIDIA confirmed the rumors of a minor design flaw but noted that the shortcomings were rectified by making a few minor changes to the photomask - a specific template that is used to create bespoke patterns on semiconductor wafers. Critically, the company announced at the time that it expected to start shipping Blackwell products in the December-ending quarter, with Hopper shipments also expected to increase.

Now, Wall Street appears to be front-running NVIDIA's relatively cautious guidance by going a giant step forward. To wit, Morgan Stanley has now disclosed that it expects NVIDIA to ship 450,000 Blackwell chips in the December-ending quarter, earning ~$10 billion in revenue from this architecture alone:

While Morgan Stanley concedes that NVIDIA is still in the process of resolving a few "technical challenges" with its GB200 server racks, the Wall Street titan posits a qualifier that such issues are a part of a "normal debugging process for new product launches."

What's more, Morgan Stanley still sees a very healthy demand profile